S&P 500   3,258.96 (+0.38%)
DOW   26,848.56 (+0.12%)
QQQ   268.72 (+1.25%)
AAPL   110.57 (+2.17%)
MSFT   206.36 (+1.56%)
FB   251.04 (+0.61%)
GOOGL   1,427.77 (+0.35%)
AMZN   3,048.00 (+0.93%)
TSLA   406.88 (+4.92%)
NVDA   505.05 (+2.25%)
BABA   267.54 (-0.81%)
CGC   13.94 (-2.31%)
GE   6.05 (-0.17%)
MU   48.48 (-2.00%)
AMD   76.67 (+1.12%)
T   27.82 (-0.78%)
F   6.55 (-1.65%)
ACB   5.00 (-3.85%)
GILD   62.01 (-0.39%)
NFLX   477.38 (+0.91%)
DIS   122.69 (+0.16%)
BAC   23.22 (-0.51%)
BA   151.22 (+3.54%)
S&P 500   3,258.96 (+0.38%)
DOW   26,848.56 (+0.12%)
QQQ   268.72 (+1.25%)
AAPL   110.57 (+2.17%)
MSFT   206.36 (+1.56%)
FB   251.04 (+0.61%)
GOOGL   1,427.77 (+0.35%)
AMZN   3,048.00 (+0.93%)
TSLA   406.88 (+4.92%)
NVDA   505.05 (+2.25%)
BABA   267.54 (-0.81%)
CGC   13.94 (-2.31%)
GE   6.05 (-0.17%)
MU   48.48 (-2.00%)
AMD   76.67 (+1.12%)
T   27.82 (-0.78%)
F   6.55 (-1.65%)
ACB   5.00 (-3.85%)
GILD   62.01 (-0.39%)
NFLX   477.38 (+0.91%)
DIS   122.69 (+0.16%)
BAC   23.22 (-0.51%)
BA   151.22 (+3.54%)
S&P 500   3,258.96 (+0.38%)
DOW   26,848.56 (+0.12%)
QQQ   268.72 (+1.25%)
AAPL   110.57 (+2.17%)
MSFT   206.36 (+1.56%)
FB   251.04 (+0.61%)
GOOGL   1,427.77 (+0.35%)
AMZN   3,048.00 (+0.93%)
TSLA   406.88 (+4.92%)
NVDA   505.05 (+2.25%)
BABA   267.54 (-0.81%)
CGC   13.94 (-2.31%)
GE   6.05 (-0.17%)
MU   48.48 (-2.00%)
AMD   76.67 (+1.12%)
T   27.82 (-0.78%)
F   6.55 (-1.65%)
ACB   5.00 (-3.85%)
GILD   62.01 (-0.39%)
NFLX   477.38 (+0.91%)
DIS   122.69 (+0.16%)
BAC   23.22 (-0.51%)
BA   151.22 (+3.54%)
S&P 500   3,258.96 (+0.38%)
DOW   26,848.56 (+0.12%)
QQQ   268.72 (+1.25%)
AAPL   110.57 (+2.17%)
MSFT   206.36 (+1.56%)
FB   251.04 (+0.61%)
GOOGL   1,427.77 (+0.35%)
AMZN   3,048.00 (+0.93%)
TSLA   406.88 (+4.92%)
NVDA   505.05 (+2.25%)
BABA   267.54 (-0.81%)
CGC   13.94 (-2.31%)
GE   6.05 (-0.17%)
MU   48.48 (-2.00%)
AMD   76.67 (+1.12%)
T   27.82 (-0.78%)
F   6.55 (-1.65%)
ACB   5.00 (-3.85%)
GILD   62.01 (-0.39%)
NFLX   477.38 (+0.91%)
DIS   122.69 (+0.16%)
BAC   23.22 (-0.51%)
BA   151.22 (+3.54%)
Log in
OTCMKTS:VVCIF

VIVO Cannabis Stock Forecast, Price & News

$0.13
-0.01 (-7.27 %)
(As of 09/24/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.12
Now: $0.13
$0.14
50-Day Range
$0.13
MA: $0.17
$0.21
52-Week Range
$0.11
Now: $0.13
$0.40
Volume91,302 shs
Average Volume157,697 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
VIVO Cannabis Inc. manufactures and distributes medical cannabis. The company was formerly known as ABcann Global Corporation and changed its name to VIVO Cannabis Inc. in August 2018. The company is headquartered in Napanee, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.31 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:VVCIF
CUSIPN/A
CIKN/A
Phone855-322-2266

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
$0.13
-0.01 (-7.27 %)
(As of 09/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VVCIF News and Ratings via Email

Sign-up to receive the latest news and ratings for VVCIF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











VIVO Cannabis (OTCMKTS:VVCIF) Frequently Asked Questions

How has VIVO Cannabis' stock been impacted by COVID-19?

VIVO Cannabis' stock was trading at $0.1620 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, VVCIF shares have decreased by 21.3% and is now trading at $0.1275.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of VIVO Cannabis?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VIVO Cannabis in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for VIVO Cannabis
.

What price target have analysts set for VVCIF?

2 brokerages have issued twelve-month price targets for VIVO Cannabis' stock. Their forecasts range from $0.70 to $0.70. On average, they anticipate VIVO Cannabis' share price to reach $0.70 in the next twelve months. This suggests a possible upside of 449.0% from the stock's current price.
View analysts' price targets for VIVO Cannabis
.

Are investors shorting VIVO Cannabis?

VIVO Cannabis saw a increase in short interest in August. As of August 31st, there was short interest totaling 628,900 shares, an increase of 32.3% from the August 15th total of 475,300 shares. Based on an average daily volume of 222,900 shares, the short-interest ratio is currently 2.8 days.
View VIVO Cannabis' Short Interest
.

Who are some of VIVO Cannabis' key competitors?

Who are VIVO Cannabis' key executives?

VIVO Cannabis' management team includes the following people:
  • Mr. Barry Fishman, CEO & Director (Age 62)
  • Dr. Michael Scott Bumby, Chief Financial Officer (Age 55)
  • Mr. Andrew LaCroix, VP of International Bus. & Gen. Counsel (Age 49)
  • Ms. Ying Guan, VP of Napanee Operations & Sec. (Age 37)
  • Mr. Daniel Laflamme, COO & Director

What is VIVO Cannabis' stock symbol?

VIVO Cannabis trades on the OTCMKTS under the ticker symbol "VVCIF."

How do I buy shares of VIVO Cannabis?

Shares of VVCIF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is VIVO Cannabis' stock price today?

One share of VVCIF stock can currently be purchased for approximately $0.13.

What is VIVO Cannabis' official website?

The official website for VIVO Cannabis is vivocannabis.com.

How can I contact VIVO Cannabis?

The company can be reached via phone at 855-322-2266.

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.